Gyre Therapeutics Inc. (GYRE : NASDAQ)
Common Stock
$6.70
USD
+0.00 (%)
Last updated: 2026-09-17
Get GYRE alerts:
GYRE
Gyre Therapeutics Inc.
WealthAwesomePerformance
1 Day
+0.15%
1 Week
-3.60%
1 Month
-1.62%
YTD
+10.20%
Key Statistics
Market Cap
$710.43M
52W High
$9.42
52W Low
$5.44
P/E Ratio
-
50 Day MA
$6.48
200 Day MA
$7.11
Beta
4.83
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $6.80 | $7.20 | $6.80 | $7.18 | $7.18 | 143,200 |
| 9/16/2026 | $6.70 | $6.86 | $6.59 | $6.70 | $6.70 | 126,400 |
| 9/15/2026 | $6.69 | $6.72 | $6.46 | $6.69 | $6.69 | 97,800 |
| 9/14/2026 | $6.82 | $7.04 | $6.69 | $6.69 | $6.69 | 104,100 |
| 9/11/2026 | $6.86 | $6.95 | $6.73 | $6.73 | $6.73 | 69,800 |
| 9/10/2026 | $6.93 | $6.96 | $6.74 | $6.74 | $6.74 | 83,100 |
| 9/9/2026 | $7.17 | $7.27 | $6.94 | $6.95 | $6.95 | 104,700 |
| 9/8/2026 | $6.85 | $7.20 | $6.85 | $7.17 | $7.17 | 239,900 |
| 9/4/2026 | $6.44 | $6.89 | $6.41 | $6.86 | $6.86 | 56,000 |
| 9/3/2026 | $6.37 | $6.54 | $6.36 | $6.44 | $6.44 | 41,200 |
Analyst Price Targets
Based on 1 analyst covering GYRE · as of Sep 17, 2026
Wall Street analysts forecast GYRE stock price to rise 178.6% over the next 12 months.
Consensus
Strong Buy5.00 / 5.00
Avg. Target
US$18.67
+178.6% Upside
Current Price
US$6.70
Last close
Analyst Breakdown (1 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GYRE's historical volatility
30-Day Vol
46.4%
Annualized
90-Day Vol
52.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$8.58
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$7.62 | US$6.49 – US$8.94 |
| 60 trading days | US$8.09 | US$6.45 – US$10.14 |
| 90 trading days | US$8.58 | US$6.50 – US$11.33 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Financials
- Revenue (TTM)
- $109.82M
- EBITDA
- $-12.13M
- Profit Margin
- -19.33%
- ROE (TTM)
- -17.44%
- EPS (Diluted)
- -0.21
- Book Value
- 1.02
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GYRE.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |